[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556485":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":19,"centralContacts":19,"locations":19,"responsibleParty":20,"collaborators":19,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":19,"eligibilityCriteria":28,"healthyVolunteers":29,"sex":30,"minAge":31,"maxAge":32,"enrollmentInfo":33,"targetDuration":19,"studyType":36,"phases":37,"briefSummary":39,"conditions":40,"keywords":19,"overallStatus":43,"whyStopped":19,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":19},{"fullName":5,"class":6},"The First Hospital of Jilin University","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Cisplatin, oxaliplatin, tegafur.","EXPERIMENTAL",[12],"Drug: cisplatin oxaliplatin tegafur",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","cisplatin oxaliplatin tegafur","Within 48 hours postoperative, the first infusion was performed with 3000-4000 ml of saline and 50 mg\u002Fm2 cisplatin at 43°C, with an infusion rate of 600 ml\u002Fmin for a duration of 2 hours. During treatment, close attention is given to the patient's heart rate, blood pressure, oxygenation, and other vital signs. A total of 2 HIPEC treatments were conducted, each 48 hours apart. Systemic chemotherapy is initiated 3-4 weeks postoperative for 6-8 cycles using SOX: intravenous injection of oxaliplatin (130 mg\u002Fm2) on the first day and oral administration of tegafur (40-60 mg twice daily, with doses adjusted for body surface area: \\\u003C1.25 m2, 40 mg; 1.25m2 ≤ body surface area ≤ 1.5m2, 50mg; body surface area \\>1.5m2, 60 mg bid) from day 1 to 14.",[9],null,{"type":21,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100556485","early-phase-1-effect-of-hipec-after-radical-surgery-on-long-term-survival-for-locally-advanced-gastric-cancer-100556485",false,"NCT06525714","Effect of HIPEC After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer","Effect of Prophylactic Hyperthermic Intraperitonal Chemotherapy（HIPEC）After Radical Surgery on Long-term Survival for Locally Advanced Gastric Cancer（cT3N+M0 and cT4aN+\u002F-M0）: A Randomized-controlled Study","Inclusion Criteria:\n\n1. Age \\>18 and ≤70 years;\n2. Male or nonpregnant female;\n3. Gastric adenocarcinoma cT3N+M0 and cT4aN+\u002F-M0 (according to the 8th edition of the AJCC TNM staging system);\n4. No distant metastasis, suitable for D2 lymph node dissection;\n5. ECOG (Eastern Cooperative Oncology Group) performance status of 0-2;\n6. No prior cytotoxic chemotherapy, radiotherapy, or immunotherapy;\n7. Written informed consent given before any study-related procedures;\n\nExclusion Criteria:\n\n1. Other cancers within the past 5 years;\n2. Distant metastasis (M1) found during surgery;\n3. ASA (American Society of Anesthesiologists) classification ≥IV and\u002For ECOG performance status \\>2;\n4. Severe liver, kidney, cardiac, pulmonary, or coagulation dysfunction, or severe underlying diseases that make the patient unable to tolerate surgery;\n5. A history of severe mental illness;\n6. History of taking steroid medications;\n7. Receiving other chemotherapy, radiotherapy, or immunotherapy;\n8. Lack of written informed consent;",true,"ALL","18 Years","70 Years",{"count":34,"type":35},302,"ESTIMATED","INTERVENTIONAL",[38],"EARLY_PHASE1","The study focuses on patients with locally advanced gastric adenocarcinoma (cT3N+M0 and cT4aN+\u002F-M0), assessing the feasibility, surgical safety, and oncological benefit of prophylactic HIPEC treatment following laparoscopic D2 radical surgery.",[41,42],"Gastric Cancer","Survival Rate","NOT_YET_RECRUITING","2024-07-29",{"date":46,"type":47},"2024-07-31","ACTUAL",{"date":49,"type":35},"2024-08",{"date":51,"type":35},"2030-07",{"name":5,"class":6}]